Recurrent Anaplastic Astrocytoma, Recurrent Anaplastic Oligoastrocytoma, Recurrent Anaplastic Oligodendroglioma, Recurrent Glioblastoma, Recurrent Gliosarcoma, Recurrent Malignant Glioma, Recurrent WHO Grade III Glioma
Conditions
Brief summary
This phase I trial studies the side effects and best dose of carboxylesterase-expressing allogeneic neural stem cells when given together with irinotecan hydrochloride in treating patients with high-grade gliomas that have come back. Placing genetically modified neural stem cells into brain tumor cells may make the tumor more sensitive to irinotecan hydrochloride. Irinotecan hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving carboxylesterase-expressing allogeneic neural stem cells and irinotecan hydrochloride may be a better treatment for high-grade gliomas.
Detailed description
PRIMARY OBJECTIVE: I. To define the recommended phase II doses (RP2D) of intracranially administered carboxylesterase-expressing allogeneic neural stem cells (hCE1m6-NSCs) in combination with intravenous irinotecan in patients with recurrent high grade glioma. SECONDARY OBJECTIVES: I. To describe the relationship between hCE1m6-NSC dose and SN-38 (SN-38) concentrations in brain interstitium. II. To characterize the relationship between intracerebral and systemic concentrations of irinotecan (irinotecan hydrochloride) and SN-38. III. To investigate the biologic activity of hCE1m6 NSCs by comparing SN-38 concentrations in the brain after treatment with hCE1m6-NSCs and irinotecan versus irinotecan alone. IV. To assess for possible development of adenovirally transduced neural stem cell (NSC) immunogenicity after first exposure and with repeat doses of NSCs. V. To describe the clinical benefit (defined as stable disease, partial response, or complete response) in patients who receive treatment with repeat cycles of NSCs and irinotecan. VI. To determine, at time of autopsy, the fate of the NSCs. OUTLINE: This is a dose-escalation study of carboxylesterase-expressing allogeneic neural stem cells. Patients receive carboxylesterase-expressing allogeneic neural stem cells intracranially over 1.5-4.5 hours on days 1 and 15 (day 1 only for patients at dose level 1) and irinotecan hydrochloride intravenously (IV) over 90 minutes on days 3 and 17. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up at 30 days, 3 and 6 months, and then annually thereafter for a minimum of 15 years.
Interventions
Given intracranially
DRUGIrinotecan
Given IV
DRUGIrinotecan Hydrochloride
Given IV
OTHERLaboratory Biomarker Analysis
Correlative studies
OTHERPharmacological Study
Correlative studies
Sponsors
City of Hope Medical Center
National Cancer Institute (NCI)
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 69 Years
Healthy volunteers
No
Inclusion criteria
* Patient must be able to understand and be willing to sign a written informed consent document * Participant must be willing to comply with study and/or follow-up procedures * Karnofsky performance status \>= 70% * Life expectancy of \>= 3 months * Histologically-confirmed diagnosis of a grade III or IV glioma (including glioblastoma, anaplastic astrocytoma, gliosarcoma, anaplastic oligodendroglioma, or anaplastic oligoastrocytoma), or has a prior, histologically-confirmed, diagnosis of a grade II glioma and now has radiographic findings consistent with a high-grade glioma (grade III or IV) * Imaging studies show evidence of recurrent tumor(s); if a patient is going to be enrolled to dose level two or higher, the patient must have a component of supratentorial disease (so as to enable placement of a Rickham reservoir/catheter) that is amenable to resection or biopsy * High-grade glioma has recurred or progressed after prior treatment with brain radiation and temozolomide * Participant must be in need of a craniotomy for tumor resection or a stereotactic brain biopsy for the purpose of diagnosis or differentiating between tumor progression versus treatment-induced effects following radiation therapy +/- chemotherapy * Based on the neurosurgeon?s judgment, there is no anticipated physical connection between the post-resection tumor cavity and the cerebral ventricles * Neurosurgeon finds the prospective participant is able to undergo neurosurgery * Any number of prior therapies is permitted; from the start of study treatment, the following time periods must have elapsed: 6 weeks from nitrosourea-containing chemotherapy, 4 weeks from non-nitrosourea-containing cytotoxic chemotherapy (except 23 days from last daily dose of temozolomide taken in a 5 of 28 day regimen), and 2 weeks from last dose of a targeted agent (except 4 weeks for bevacizumab); there is no time period requirement for prior radiation therapy * Any clinically significant toxicity from prior therapy must have improved to grade 0 or grade 1 * Absolute neutrophil count (ANC) \>= 1,500 cells/ul * Platelets \> 100,000 cells/ul * Total bilirubin =\< 2.0 mg/dl * Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase \[SGOT\]) =\< 4 times institutional upper limit of normal * Serum creatinine =\< 1.5 x the institutional upper limit of normal * Homozygous negative for the UDP glucuronosyltransferase 1 family, polypeptide A1 (UGT 1A1)\*28 allele * Absence anti-human leukocyte antigen (HLA) antibodies specific for HLA class I antigens expressed by the coagulation factor III (thromboplastin, tissue factor) (F3).cytosine deaminase (CD).carboxylesterase (CE) NSCs * Negative serum pregnancy test (women of childbearing potential only) * Agreement by females of childbearing potential and sexually active males to use an effective method of contraception while participating in this study; women of childbearing potential must have a negative pregnancy test \< 2 weeks prior to registration
Exclusion criteria
* Prior therapy with neural stem cells * Use of cytochrome P450, family 3, subfamily A, polypeptide 4 (CYP3A4) inducers including hepatic enzyme-inducing anticonvulsants (phenytoin, fosphenytoin, carbamazepine, phenobarbital, primidone, oxcarbazepine) within 2 weeks prior to start of study treatment * Use of moderate to strong CYP3A4 inhibitors within 2 weeks prior to start of study treatment * Use of drugs known to inhibit UGT1A1, such as atazanir, gemfibrozil, indinavir, or ketoconazole, within 2 weeks prior to start of study treatment * Co-medication that may interfere with study results; e.g. immuno-suppressive agents other than corticosteroids, such as systemic cyclosporine and tacrolimus; consult principal investigator for questions, including necessary washout period for the specific drug * Flucytosine within 2 weeks prior to start of study treatment * Use of herbal medications * Current use (or planned use during the treatment period) of other investigational agents, or biological, chemotherapy, radiation or other anti-tumor therapy * Patient has known human immunodeficiency virus (HIV) or hepatitis C infection; baseline testing for HIV or hepatitis C is not required * Prospective participant is unable to undergo a magnetic resonance imaging (MRI) with contrast agent * Known chronic or active viral infections of the central nervous system (CNS) * Clinically significant uncontrolled illness * Active infection requiring antibiotics * Diagnosis of Gilbert?s disease * History of allergic reactions attributed to compounds of similar chemical or biologic composition to irinotecan * Known sensitivity to any of the products to be administered during dosing * Any other active malignancy * Pregnant women and women who are lactating * Serious medical or psychiatric illness that could, in the investigator?s opinion, potentially interfere with the safety monitoring requirements and completion of treatment according to this protocol * Prospective participants who, in the opinion of the investigator, may not be able to comply with all study procedures (including compliance issues related to feasibility/logistics)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants Experiencing a Dose-limiting Toxicity (DLT) | 28 days post first dose of NSC treatment on day 1, cycle 1 | Toxicities will be graded using NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. A DLT is defined as an adverse event that is related to the administration of NSCs and/or irinotecan, occurs during the first treatment cycle and meets any of the following: 1. Received less than 80% of study treatments except due to CNS toxicity 2. Grade 4 thrombocytopenia or anemia or neutropenia lasting \> 7 days 3. Febrile neutropenia with ANC \< 0.5 x10\^9/L 4. Grade 3 central nervous system (CNS) disorder lasting \> 7 days not attributed to tumor or surgery and not present at baseline 5. Second occurrence of grade 3 CNS disorder not attributed to tumor or surgery and not present at baseline 6. Any grade 4 CNS disorder not attributed to tumor or surgery and not present at baseline 7. Grade 3 toxicity despite therapy lasting \> 7 days 8. Grade 3 toxicity resulting in study agent discontinuation 9. Grade 4 toxicity, except grade 4 diarrhea responding to therapy within 3 days |
| Number of Participants With Grade 3 or Higher Toxicity Profile Attributed to NSCs | Followed 30 days post treatment for all toxicities (min=33,max 142 days), up to 5 years for gene therapy toxicities | Grade 3 or higher toxicity profile as assessed by the NCI CTCAE version version 4.0. Toxicities reported are possibly, probably or definitely related to NSCs. |
| Number of Participants With Grade 3 or Higher Toxicity Profile Attributed to Irinotecan | Followed 30 days post treatment for all toxicities (min=33,max 142 days), up to 5 years for gene therapy toxicities | Grade 3 or higher toxicity profile as assessed by the NCI CTCAE version version 4.0. Toxicities reported are possibly, probably or definitely related to Irinotecan. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Median Ratio of SN-38 Area Under the Curve (AUC) to CPT-11 AUC in Plasma | Pre-dose, at 90 minutes (just prior to the end of the infusion), and then at 30 minutes, 1, 2, 4, 8, 24, and 48 hours after the end of the infusion after day 1, cycle 1 | Pharmacokinetic data from patients who undergo intracerebral microdialysis will be summarized using descriptive statistics. hCE1m6-NSC dose and liposomal SN-38 concentrations in brain interstitium using microdialysis data from the patients treated with the initial neural stem cells (NSC) doses and from the patients in the cohort treated with the highest NSC dose. Ratios are reported as ratio x 100. |
| Median Ratio of SN-38 AUC to CPT-11 AUC in the Brain | Pre-dose, at 90 minutes (just prior to the end of the infusion), and then at 30 minutes, 1, 2, 4, 8, 24, and 48 hours after the end of the infusion after day 1, cycle 1 | Pharmacokinetic data from patients who undergo intracerebral microdialysis will be summarized using descriptive statistics. hCE1m6-NSC dose and liposomal SN-38 concentrations in brain interstitium using microdialysis data from the patients treated with the initial neural stem cells (NSC) doses and from the patients in the cohort treated with the highest NSC dose. Ratio is reported as ratio x 100 |
| Number of Participants With Clinical Benefit Defined by Response Assessment in Neuro-Oncology (RANO) | Until death or disease progression, a median of 2 months, up to 6 months | Clinical benefit is defined by participants achieving stable disease (SD), partial response (PR), or complete response (CR). CR: Complete disappearance of all enhancing disease (measurable and nonmeasureable) that is sustained for at least 4 weeks, stable or improved non-enhancing FLAIR/T2 lesions, no new lesions, off corticosteroids (physiologic replacement doses allowed), and neurologically stable or improved. PR: ≥ 50% decrease of all measurable enhancing lesions, sustained for at least 4 weeks, no progression of non-measurable disease, stable or improved non-enhancing FLAIR/T2 lesions, no new lesions, corticosteroid dose stable or reduced (compared to baseline), and neurologically stable or improved. SD: Does not qualify for CR, PR, or PD, stable non-enhancing FLAIR/T2 lesions, stable or reduced corticosteroids (compared to baseline), clinically stable. |
Countries
United States
Contacts
PRINCIPAL_INVESTIGATORJana L Portnow
City of Hope Medical Center
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Dose Level 1: 5x10^7 (1 Dose) Carboxylesterase-expressing Allogeneic Neural Stem Cells: Given intracranially, 5x10\^7 (1 dose)
Irinotecan: 180 mg/m2 | 4 |
| Dose Level 2: 5x10^7 (2 Doses) Carboxylesterase-expressing Allogeneic Neural Stem Cells: Given intracranially, 5x10\^7 (2 doses)
Irinotecan: 180 mg/m2 | 3 |
| Dose Level 3: 1x10^8 (2 Doses) Carboxylesterase-expressing Allogeneic Neural Stem Cells: Given intracranially, 1x10\^8 (2 doses)
Irinotecan: 180 mg/m2 | 4 |
| Dose Level 4: 1.5x10^8 (2 Doses) Carboxylesterase-expressing Allogeneic Neural Stem Cells: Given intracranially, 1.5x10\^8 (2 doses)
Irinotecan: 180 mg/m2 | 7 |
| Total | 18 |
Baseline characteristics
| Characteristic | Total | Dose Level 4: 1.5x10^8 (2 Doses) | Dose Level 1: 5x10^7 (1 Dose) | Dose Level 2: 5x10^7 (2 Doses) | Dose Level 3: 1x10^8 (2 Doses) |
|---|---|---|---|---|---|
| Age, Categorical <=18 years | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Age, Categorical >=65 years | 1 Participants | 1 Participants | 0 Participants | 0 Participants | 0 Participants |
| Age, Categorical Between 18 and 65 years | 17 Participants | 6 Participants | 4 Participants | 3 Participants | 4 Participants |
| Age, Continuous | 51 years | 44 years | 49.5 years | 56 years | 56.5 years |
| Ethnicity (NIH/OMB) Hispanic or Latino | 9 Participants | 4 Participants | 1 Participants | 1 Participants | 3 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 9 Participants | 3 Participants | 3 Participants | 2 Participants | 1 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 1 Participants | 0 Participants | 0 Participants | 1 Participants | 0 Participants |
| Race (NIH/OMB) Black or African American | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) White | 17 Participants | 7 Participants | 4 Participants | 2 Participants | 4 Participants |
| Region of Enrollment United States | 18 Participants | 7 Participants | 4 Participants | 3 Participants | 4 Participants |
| Sex: Female, Male Female | 3 Participants | 0 Participants | 0 Participants | 2 Participants | 1 Participants |
| Sex: Female, Male Male | 15 Participants | 7 Participants | 4 Participants | 1 Participants | 3 Participants |
| Tumor Type anaplastic astrocytoma, anaplastic oligodendroglioma, anaplastic oligoastrocytoma | 4 Participants | 2 Participants | 1 Participants | 0 Participants | 1 Participants |
| Tumor Type glioblastoma, gliosarcoma | 14 Participants | 5 Participants | 3 Participants | 3 Participants | 3 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk |
|---|---|---|---|---|
| deaths Total, all-cause mortality | 4 / 4 | 3 / 3 | 4 / 4 | 6 / 7 |
| other Total, other adverse events | 4 / 4 | 3 / 3 | 4 / 4 | 7 / 7 |
| serious Total, serious adverse events | 0 / 4 | 1 / 3 | 2 / 4 | 5 / 7 |
Outcome results
Primary
Number of Participants Experiencing a Dose-limiting Toxicity (DLT)
Toxicities will be graded using NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. A DLT is defined as an adverse event that is related to the administration of NSCs and/or irinotecan, occurs during the first treatment cycle and meets any of the following: 1. Received less than 80% of study treatments except due to CNS toxicity 2. Grade 4 thrombocytopenia or anemia or neutropenia lasting \> 7 days 3. Febrile neutropenia with ANC \< 0.5 x10\^9/L 4. Grade 3 central nervous system (CNS) disorder lasting \> 7 days not attributed to tumor or surgery and not present at baseline 5. Second occurrence of grade 3 CNS disorder not attributed to tumor or surgery and not present at baseline 6. Any grade 4 CNS disorder not attributed to tumor or surgery and not present at baseline 7. Grade 3 toxicity despite therapy lasting \> 7 days 8. Grade 3 toxicity resulting in study agent discontinuation 9. Grade 4 toxicity, except grade 4 diarrhea responding to therapy within 3 days
Time frame: 28 days post first dose of NSC treatment on day 1, cycle 1
Population: 1 participant in each of dose levels 1, 3, and 4 was not evaluable for DLT because they were removed from the study due to adverse events not related to study treatment.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Dose Level 1: 5x10^7 (1 Dose) | Number of Participants Experiencing a Dose-limiting Toxicity (DLT) | 0 Participants |
| Dose Level 2: 5x10^7 (2 Doses) | Number of Participants Experiencing a Dose-limiting Toxicity (DLT) | 0 Participants |
| Dose Level 3: 1x10^8 (2 Doses) | Number of Participants Experiencing a Dose-limiting Toxicity (DLT) | 0 Participants |
| Dose Level 4: 1.5x10^8 (2 Doses) | Number of Participants Experiencing a Dose-limiting Toxicity (DLT) | 1 Participants |
Primary
Number of Participants With Grade 3 or Higher Toxicity Profile Attributed to Irinotecan
Grade 3 or higher toxicity profile as assessed by the NCI CTCAE version version 4.0. Toxicities reported are possibly, probably or definitely related to Irinotecan.
Time frame: Followed 30 days post treatment for all toxicities (min=33,max 142 days), up to 5 years for gene therapy toxicities
| Arm | Measure | Group | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|---|
| Dose Level 1: 5x10^7 (1 Dose) | Number of Participants With Grade 3 or Higher Toxicity Profile Attributed to Irinotecan | Meningitis | No | 4 Participants |
| Dose Level 1: 5x10^7 (1 Dose) | Number of Participants With Grade 3 or Higher Toxicity Profile Attributed to Irinotecan | Catheter related infection | No | 4 Participants |
| Dose Level 1: 5x10^7 (1 Dose) | Number of Participants With Grade 3 or Higher Toxicity Profile Attributed to Irinotecan | Catheter related infection | Yes | 0 Participants |
| Dose Level 1: 5x10^7 (1 Dose) | Number of Participants With Grade 3 or Higher Toxicity Profile Attributed to Irinotecan | White blood cell decreased | Yes | 1 Participants |
| Dose Level 1: 5x10^7 (1 Dose) | Number of Participants With Grade 3 or Higher Toxicity Profile Attributed to Irinotecan | Hypophosphatemia | No | 4 Participants |
| Dose Level 1: 5x10^7 (1 Dose) | Number of Participants With Grade 3 or Higher Toxicity Profile Attributed to Irinotecan | Fatigue | No | 4 Participants |
| Dose Level 1: 5x10^7 (1 Dose) | Number of Participants With Grade 3 or Higher Toxicity Profile Attributed to Irinotecan | Platelet count decreased | Yes | 1 Participants |
| Dose Level 1: 5x10^7 (1 Dose) | Number of Participants With Grade 3 or Higher Toxicity Profile Attributed to Irinotecan | White blood cell decreased | No | 3 Participants |
| Dose Level 1: 5x10^7 (1 Dose) | Number of Participants With Grade 3 or Higher Toxicity Profile Attributed to Irinotecan | Brain abscess | Yes | 0 Participants |
| Dose Level 1: 5x10^7 (1 Dose) | Number of Participants With Grade 3 or Higher Toxicity Profile Attributed to Irinotecan | Fatigue | Yes | 0 Participants |
| Dose Level 1: 5x10^7 (1 Dose) | Number of Participants With Grade 3 or Higher Toxicity Profile Attributed to Irinotecan | Brain abscess | No | 4 Participants |
| Dose Level 1: 5x10^7 (1 Dose) | Number of Participants With Grade 3 or Higher Toxicity Profile Attributed to Irinotecan | Meningitis | Yes | 0 Participants |
| Dose Level 1: 5x10^7 (1 Dose) | Number of Participants With Grade 3 or Higher Toxicity Profile Attributed to Irinotecan | Hypophosphatemia | Yes | 0 Participants |
| Dose Level 1: 5x10^7 (1 Dose) | Number of Participants With Grade 3 or Higher Toxicity Profile Attributed to Irinotecan | Platelet count decreased | No | 3 Participants |
| Dose Level 2: 5x10^7 (2 Doses) | Number of Participants With Grade 3 or Higher Toxicity Profile Attributed to Irinotecan | Fatigue | Yes | 0 Participants |
| Dose Level 2: 5x10^7 (2 Doses) | Number of Participants With Grade 3 or Higher Toxicity Profile Attributed to Irinotecan | Meningitis | No | 2 Participants |
| Dose Level 2: 5x10^7 (2 Doses) | Number of Participants With Grade 3 or Higher Toxicity Profile Attributed to Irinotecan | Hypophosphatemia | Yes | 1 Participants |
| Dose Level 2: 5x10^7 (2 Doses) | Number of Participants With Grade 3 or Higher Toxicity Profile Attributed to Irinotecan | Hypophosphatemia | No | 2 Participants |
| Dose Level 2: 5x10^7 (2 Doses) | Number of Participants With Grade 3 or Higher Toxicity Profile Attributed to Irinotecan | Platelet count decreased | Yes | 0 Participants |
| Dose Level 2: 5x10^7 (2 Doses) | Number of Participants With Grade 3 or Higher Toxicity Profile Attributed to Irinotecan | Catheter related infection | Yes | 0 Participants |
| Dose Level 2: 5x10^7 (2 Doses) | Number of Participants With Grade 3 or Higher Toxicity Profile Attributed to Irinotecan | Platelet count decreased | No | 3 Participants |
| Dose Level 2: 5x10^7 (2 Doses) | Number of Participants With Grade 3 or Higher Toxicity Profile Attributed to Irinotecan | Catheter related infection | No | 3 Participants |
| Dose Level 2: 5x10^7 (2 Doses) | Number of Participants With Grade 3 or Higher Toxicity Profile Attributed to Irinotecan | White blood cell decreased | Yes | 0 Participants |
| Dose Level 2: 5x10^7 (2 Doses) | Number of Participants With Grade 3 or Higher Toxicity Profile Attributed to Irinotecan | Brain abscess | No | 3 Participants |
| Dose Level 2: 5x10^7 (2 Doses) | Number of Participants With Grade 3 or Higher Toxicity Profile Attributed to Irinotecan | White blood cell decreased | No | 3 Participants |
| Dose Level 2: 5x10^7 (2 Doses) | Number of Participants With Grade 3 or Higher Toxicity Profile Attributed to Irinotecan | Fatigue | No | 3 Participants |
| Dose Level 2: 5x10^7 (2 Doses) | Number of Participants With Grade 3 or Higher Toxicity Profile Attributed to Irinotecan | Meningitis | Yes | 1 Participants |
| Dose Level 2: 5x10^7 (2 Doses) | Number of Participants With Grade 3 or Higher Toxicity Profile Attributed to Irinotecan | Brain abscess | Yes | 0 Participants |
| Dose Level 3: 1x10^8 (2 Doses) | Number of Participants With Grade 3 or Higher Toxicity Profile Attributed to Irinotecan | Hypophosphatemia | Yes | 0 Participants |
| Dose Level 3: 1x10^8 (2 Doses) | Number of Participants With Grade 3 or Higher Toxicity Profile Attributed to Irinotecan | Fatigue | Yes | 1 Participants |
| Dose Level 3: 1x10^8 (2 Doses) | Number of Participants With Grade 3 or Higher Toxicity Profile Attributed to Irinotecan | Fatigue | No | 3 Participants |
| Dose Level 3: 1x10^8 (2 Doses) | Number of Participants With Grade 3 or Higher Toxicity Profile Attributed to Irinotecan | Platelet count decreased | Yes | 0 Participants |
| Dose Level 3: 1x10^8 (2 Doses) | Number of Participants With Grade 3 or Higher Toxicity Profile Attributed to Irinotecan | Platelet count decreased | No | 4 Participants |
| Dose Level 3: 1x10^8 (2 Doses) | Number of Participants With Grade 3 or Higher Toxicity Profile Attributed to Irinotecan | White blood cell decreased | Yes | 0 Participants |
| Dose Level 3: 1x10^8 (2 Doses) | Number of Participants With Grade 3 or Higher Toxicity Profile Attributed to Irinotecan | White blood cell decreased | No | 4 Participants |
| Dose Level 3: 1x10^8 (2 Doses) | Number of Participants With Grade 3 or Higher Toxicity Profile Attributed to Irinotecan | Meningitis | Yes | 0 Participants |
| Dose Level 3: 1x10^8 (2 Doses) | Number of Participants With Grade 3 or Higher Toxicity Profile Attributed to Irinotecan | Meningitis | No | 4 Participants |
| Dose Level 3: 1x10^8 (2 Doses) | Number of Participants With Grade 3 or Higher Toxicity Profile Attributed to Irinotecan | Hypophosphatemia | No | 4 Participants |
| Dose Level 3: 1x10^8 (2 Doses) | Number of Participants With Grade 3 or Higher Toxicity Profile Attributed to Irinotecan | Brain abscess | Yes | 1 Participants |
| Dose Level 3: 1x10^8 (2 Doses) | Number of Participants With Grade 3 or Higher Toxicity Profile Attributed to Irinotecan | Brain abscess | No | 3 Participants |
| Dose Level 3: 1x10^8 (2 Doses) | Number of Participants With Grade 3 or Higher Toxicity Profile Attributed to Irinotecan | Catheter related infection | Yes | 0 Participants |
| Dose Level 3: 1x10^8 (2 Doses) | Number of Participants With Grade 3 or Higher Toxicity Profile Attributed to Irinotecan | Catheter related infection | No | 4 Participants |
| Dose Level 4: 1.5x10^8 (2 Doses) | Number of Participants With Grade 3 or Higher Toxicity Profile Attributed to Irinotecan | Fatigue | No | 7 Participants |
| Dose Level 4: 1.5x10^8 (2 Doses) | Number of Participants With Grade 3 or Higher Toxicity Profile Attributed to Irinotecan | Brain abscess | Yes | 0 Participants |
| Dose Level 4: 1.5x10^8 (2 Doses) | Number of Participants With Grade 3 or Higher Toxicity Profile Attributed to Irinotecan | White blood cell decreased | No | 7 Participants |
| Dose Level 4: 1.5x10^8 (2 Doses) | Number of Participants With Grade 3 or Higher Toxicity Profile Attributed to Irinotecan | White blood cell decreased | Yes | 0 Participants |
| Dose Level 4: 1.5x10^8 (2 Doses) | Number of Participants With Grade 3 or Higher Toxicity Profile Attributed to Irinotecan | Fatigue | Yes | 0 Participants |
| Dose Level 4: 1.5x10^8 (2 Doses) | Number of Participants With Grade 3 or Higher Toxicity Profile Attributed to Irinotecan | Brain abscess | No | 7 Participants |
| Dose Level 4: 1.5x10^8 (2 Doses) | Number of Participants With Grade 3 or Higher Toxicity Profile Attributed to Irinotecan | Platelet count decreased | No | 7 Participants |
| Dose Level 4: 1.5x10^8 (2 Doses) | Number of Participants With Grade 3 or Higher Toxicity Profile Attributed to Irinotecan | Platelet count decreased | Yes | 0 Participants |
| Dose Level 4: 1.5x10^8 (2 Doses) | Number of Participants With Grade 3 or Higher Toxicity Profile Attributed to Irinotecan | Catheter related infection | No | 6 Participants |
| Dose Level 4: 1.5x10^8 (2 Doses) | Number of Participants With Grade 3 or Higher Toxicity Profile Attributed to Irinotecan | Hypophosphatemia | Yes | 0 Participants |
| Dose Level 4: 1.5x10^8 (2 Doses) | Number of Participants With Grade 3 or Higher Toxicity Profile Attributed to Irinotecan | Hypophosphatemia | No | 7 Participants |
| Dose Level 4: 1.5x10^8 (2 Doses) | Number of Participants With Grade 3 or Higher Toxicity Profile Attributed to Irinotecan | Catheter related infection | Yes | 1 Participants |
| Dose Level 4: 1.5x10^8 (2 Doses) | Number of Participants With Grade 3 or Higher Toxicity Profile Attributed to Irinotecan | Meningitis | No | 7 Participants |
| Dose Level 4: 1.5x10^8 (2 Doses) | Number of Participants With Grade 3 or Higher Toxicity Profile Attributed to Irinotecan | Meningitis | Yes | 0 Participants |
Primary
Number of Participants With Grade 3 or Higher Toxicity Profile Attributed to NSCs
Grade 3 or higher toxicity profile as assessed by the NCI CTCAE version version 4.0. Toxicities reported are possibly, probably or definitely related to NSCs.
Time frame: Followed 30 days post treatment for all toxicities (min=33,max 142 days), up to 5 years for gene therapy toxicities
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Dose Level 1: 5x10^7 (1 Dose) | Number of Participants With Grade 3 or Higher Toxicity Profile Attributed to NSCs | 0 Participants |
| Dose Level 2: 5x10^7 (2 Doses) | Number of Participants With Grade 3 or Higher Toxicity Profile Attributed to NSCs | 0 Participants |
| Dose Level 3: 1x10^8 (2 Doses) | Number of Participants With Grade 3 or Higher Toxicity Profile Attributed to NSCs | 0 Participants |
| Dose Level 4: 1.5x10^8 (2 Doses) | Number of Participants With Grade 3 or Higher Toxicity Profile Attributed to NSCs | 0 Participants |
Secondary
Median Ratio of SN-38 Area Under the Curve (AUC) to CPT-11 AUC in Plasma
Pharmacokinetic data from patients who undergo intracerebral microdialysis will be summarized using descriptive statistics. hCE1m6-NSC dose and liposomal SN-38 concentrations in brain interstitium using microdialysis data from the patients treated with the initial neural stem cells (NSC) doses and from the patients in the cohort treated with the highest NSC dose. Ratios are reported as ratio x 100.
Time frame: Pre-dose, at 90 minutes (just prior to the end of the infusion), and then at 30 minutes, 1, 2, 4, 8, 24, and 48 hours after the end of the infusion after day 1, cycle 1
Population: All 4 participants in dose level 3 and one participant in dose level 4 did not have plasma samples collected.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Dose Level 1: 5x10^7 (1 Dose) | Median Ratio of SN-38 Area Under the Curve (AUC) to CPT-11 AUC in Plasma | 4.8 ratio x 100 |
| Dose Level 2: 5x10^7 (2 Doses) | Median Ratio of SN-38 Area Under the Curve (AUC) to CPT-11 AUC in Plasma | 0.8 ratio x 100 |
| Dose Level 3: 1x10^8 (2 Doses) | Median Ratio of SN-38 Area Under the Curve (AUC) to CPT-11 AUC in Plasma | 2.35 ratio x 100 |
Secondary
Median Ratio of SN-38 AUC to CPT-11 AUC in the Brain
Pharmacokinetic data from patients who undergo intracerebral microdialysis will be summarized using descriptive statistics. hCE1m6-NSC dose and liposomal SN-38 concentrations in brain interstitium using microdialysis data from the patients treated with the initial neural stem cells (NSC) doses and from the patients in the cohort treated with the highest NSC dose. Ratio is reported as ratio x 100
Time frame: Pre-dose, at 90 minutes (just prior to the end of the infusion), and then at 30 minutes, 1, 2, 4, 8, 24, and 48 hours after the end of the infusion after day 1, cycle 1
Population: All 4 participants in dose level 3 did not have brain samples collected.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Dose Level 1: 5x10^7 (1 Dose) | Median Ratio of SN-38 AUC to CPT-11 AUC in the Brain | 6.9 ratio x 100 |
| Dose Level 2: 5x10^7 (2 Doses) | Median Ratio of SN-38 AUC to CPT-11 AUC in the Brain | 8.8 ratio x 100 |
| Dose Level 3: 1x10^8 (2 Doses) | Median Ratio of SN-38 AUC to CPT-11 AUC in the Brain | 12.2 ratio x 100 |
Secondary
Number of Participants With Clinical Benefit Defined by Response Assessment in Neuro-Oncology (RANO)
Clinical benefit is defined by participants achieving stable disease (SD), partial response (PR), or complete response (CR). CR: Complete disappearance of all enhancing disease (measurable and nonmeasureable) that is sustained for at least 4 weeks, stable or improved non-enhancing FLAIR/T2 lesions, no new lesions, off corticosteroids (physiologic replacement doses allowed), and neurologically stable or improved. PR: ≥ 50% decrease of all measurable enhancing lesions, sustained for at least 4 weeks, no progression of non-measurable disease, stable or improved non-enhancing FLAIR/T2 lesions, no new lesions, corticosteroid dose stable or reduced (compared to baseline), and neurologically stable or improved. SD: Does not qualify for CR, PR, or PD, stable non-enhancing FLAIR/T2 lesions, stable or reduced corticosteroids (compared to baseline), clinically stable.
Time frame: Until death or disease progression, a median of 2 months, up to 6 months
Population: 1 participant in dose levels 1 and 3 and 2 is dose level 4 were unevaluable for response due to not receiving the full treatment.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Dose Level 1: 5x10^7 (1 Dose) | Number of Participants With Clinical Benefit Defined by Response Assessment in Neuro-Oncology (RANO) | 0 Participants |
| Dose Level 2: 5x10^7 (2 Doses) | Number of Participants With Clinical Benefit Defined by Response Assessment in Neuro-Oncology (RANO) | 1 Participants |
| Dose Level 3: 1x10^8 (2 Doses) | Number of Participants With Clinical Benefit Defined by Response Assessment in Neuro-Oncology (RANO) | 1 Participants |
| Dose Level 4: 1.5x10^8 (2 Doses) | Number of Participants With Clinical Benefit Defined by Response Assessment in Neuro-Oncology (RANO) | 3 Participants |